Literature DB >> 11264229

Effects of anti-oestrogens and beta-estradiol on calcium uptake by cardiac sarcoplasmic reticulum.

M L Dodds1, M E Kargacin, G J Kargacin.   

Abstract

1. Tamoxifen and a group of structurally similar non-steroidal, triphenolic compounds inhibit the oestrogen receptor. In addition to this action, these anti-oestrogens are known to inhibit some types of plasma membrane ion channels and other proteins through mechanisms that do not appear to involve their interactions with the estrogen receptor but could be the result of their effect on membrane lipid structure or fluidity. 2. We studied the effects of beta-estradiol and three anti-oestrogens (tamoxifen, 4-hydroxytamoxifen and clomiphene) on Ca(2+) uptake into sarcoplasmic reticulum (SR) vesicles isolated from canine cardiac ventricular tissue. 3. The antiestrogens all inhibit SR Ca(2+) uptake in a concentration-dependent manner (order of potency: tamoxifen > 4-hydroxytamoxifen > or = clomiphene). Although these compounds rapidly inhibit net Ca(2+) uptake they do not have a similar rapid effect on the ATPase activity of the SR Ca pump. beta-estradiol has no effect on Ca(2+) uptake nor does it alter the inhibitory action of tamoxifen on the SR. 4. The differences in the effects of beta-estradiol and the anti-oestrogens on cardiac SR Ca(2+) uptake do not correlate with differences in the ways in which these compounds have been reported to interact with membrane lipids. Our results are consistent, however, with direct effects on a membrane protein (possibly an SR Cl(-) or K(+) channel).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264229      PMCID: PMC1572683          DOI: 10.1038/sj.bjp.0703924

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Anti-phospholamban and protein kinase A alter the Ca2+ sensitivity and maximum velocity of Ca2+ uptake by the cardiac sarcoplasmic reticulum.

Authors:  M E Kargacin; Z Ali; G Kargacin
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

2.  Continuous monitoring of Ca2+ uptake in membrane vesicles with fura-2.

Authors:  M E Kargacin; C R Scheid; T W Honeyman
Journal:  Am J Physiol       Date:  1988-11

3.  Blockers of volume-activated Cl- currents inhibit endothelial cell proliferation.

Authors:  T Voets; G Szücs; G Droogmans; B Nilius
Journal:  Pflugers Arch       Date:  1995-11       Impact factor: 3.657

4.  Tamoxifen inhibits Ca2+ uptake by the cardiac sarcoplasmic reticulum.

Authors:  M E Kargacin; Z Ali; C A Ward; N S Pollock; G J Kargacin
Journal:  Pflugers Arch       Date:  2000-08       Impact factor: 3.657

5.  Ca2(+)-dependent binding of tamoxifen to calmodulin isolated from bovine brain.

Authors:  M C Lopes; M G Vale; A P Carvalho
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

6.  Effects of anion channel antagonists in canine colonic myocytes: comparative pharmacology of Cl-, Ca2+ and K+ currents.

Authors:  G M Dick; I D Kong; K M Sanders
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

7.  Effects of tamoxifen, tamoxifen metabolites, and nafoxidine on adenosine 3',5'-monophosphate phosphodiesterase: correlations with growth inhibitory activities but not estrogen receptor affinities.

Authors:  A Fanidi; C Courion-Guichardaz; J M Fayard; J F Pageaux; C Laugier
Journal:  Endocrinology       Date:  1989-09       Impact factor: 4.736

8.  The active metabolite hydroxytamoxifen of the anticancer drug tamoxifen induces structural changes in membranes.

Authors:  J B Custódio; L M Almeida; V M Madeira
Journal:  Biochim Biophys Acta       Date:  1993-12-12

9.  The anticancer drug tamoxifen induces changes in the physical properties of model and native membranes.

Authors:  J B Custódio; L M Almeida; V M Madeira
Journal:  Biochim Biophys Acta       Date:  1993-08-15

10.  Tamoxifen blocks chloride channels. A possible mechanism for cataract formation.

Authors:  J J Zhang; T J Jacob; M A Valverde; S P Hardy; G M Mintenig; F V Sepúlveda; D R Gill; S C Hyde; A E Trezise; C F Higgins
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

View more
  8 in total

Review 1.  Sex differences in myocardial metabolism and cardiac function: an emerging concept.

Authors:  Carin Wittnich; Luke Tan; Jack Wallen; Michael Belanger
Journal:  Pflugers Arch       Date:  2013-02-13       Impact factor: 3.657

2.  The selective estrogen receptor modulator raloxifene mitigates the effect of all-trans-retinal toxicity in photoreceptor degeneration.

Authors:  Tamar Getter; Susie Suh; Thanh Hoang; James T Handa; Zhiqian Dong; Xiuli Ma; Yuanyuan Chen; Seth Blackshaw; Krzysztof Palczewski
Journal:  J Biol Chem       Date:  2019-05-09       Impact factor: 5.157

3.  Inhibition of a cardiac sarcoplasmic reticulum chloride channel by tamoxifen.

Authors:  Sanja Beca; Evgeny Pavlov; Margaret E Kargacin; Roozbeh Aschar-Sobbi; Robert J French; Gary J Kargacin
Journal:  Pflugers Arch       Date:  2008-05-06       Impact factor: 3.657

Review 4.  Reciprocality Between Estrogen Biology and Calcium Signaling in the Cardiovascular System.

Authors:  Quang-Kim Tran
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-29       Impact factor: 5.555

5.  Tamoxifen treatment ameliorates contractile dysfunction of Duchenne muscular dystrophy stem cell-derived cardiomyocytes on bioengineered substrates.

Authors:  Foster Birnbaum; Asuka Eguchi; Gaspard Pardon; Alex C Y Chang; Helen M Blau
Journal:  NPJ Regen Med       Date:  2022-03-18

6.  Tamoxifen treatment of myocardial infarcted female rats exacerbates scar formation.

Authors:  Pedro Geraldes; Hugues Gosselin; Jean-François Tanguay; Robert Clément; Angelino Calderone
Journal:  Pflugers Arch       Date:  2007-02-07       Impact factor: 4.458

7.  In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators.

Authors:  Lei Xie; Jian Wang; Philip E Bourne
Journal:  PLoS Comput Biol       Date:  2007-09-26       Impact factor: 4.475

8.  Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.

Authors:  Sara Nagy; Patricia Hafner; Simone Schmidt; Daniela Rubino-Nacht; Sabine Schädelin; Oliver Bieri; Dirk Fischer
Journal:  Trials       Date:  2019-11-21       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.